Trevi Therapeutics (TRVI) Competitors $4.05 -0.10 (-2.41%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TRVI vs. ARVN, DAWN, ARDX, SYRE, CALT, SPRY, ANIP, SNDX, RCKT, and BCYCShould you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Arvinas (ARVN), Day One Biopharmaceuticals (DAWN), Ardelyx (ARDX), Spyre Therapeutics (SYRE), Calliditas Therapeutics AB (publ) (CALT), ARS Pharmaceuticals (SPRY), ANI Pharmaceuticals (ANIP), Syndax Pharmaceuticals (SNDX), Rocket Pharmaceuticals (RCKT), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry. Trevi Therapeutics vs. Arvinas Day One Biopharmaceuticals Ardelyx Spyre Therapeutics Calliditas Therapeutics AB (publ) ARS Pharmaceuticals ANI Pharmaceuticals Syndax Pharmaceuticals Rocket Pharmaceuticals Bicycle Therapeutics Trevi Therapeutics (NASDAQ:TRVI) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, community ranking, risk, profitability, media sentiment and institutional ownership. Does the media prefer TRVI or ARVN? In the previous week, Arvinas had 5 more articles in the media than Trevi Therapeutics. MarketBeat recorded 7 mentions for Arvinas and 2 mentions for Trevi Therapeutics. Arvinas' average media sentiment score of 0.36 beat Trevi Therapeutics' score of 0.00 indicating that Arvinas is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arvinas 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts recommend TRVI or ARVN? Trevi Therapeutics presently has a consensus price target of $9.31, suggesting a potential upside of 129.94%. Arvinas has a consensus price target of $63.50, suggesting a potential upside of 243.61%. Given Arvinas' higher probable upside, analysts clearly believe Arvinas is more favorable than Trevi Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20Arvinas 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.93 Does the MarketBeat Community favor TRVI or ARVN? Arvinas received 91 more outperform votes than Trevi Therapeutics when rated by MarketBeat users. Likewise, 67.03% of users gave Arvinas an outperform vote while only 65.28% of users gave Trevi Therapeutics an outperform vote. CompanyUnderperformOutperformTrevi TherapeuticsOutperform Votes9465.28% Underperform Votes5034.72% ArvinasOutperform Votes18567.03% Underperform Votes9132.97% Which has higher valuation and earnings, TRVI or ARVN? Trevi Therapeutics has higher earnings, but lower revenue than Arvinas. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevi TherapeuticsN/AN/A-$29.07M-$0.44-9.20Arvinas$161.10M7.88-$367.30M-$4.67-3.96 Is TRVI or ARVN more profitable? Arvinas' return on equity of -50.26% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Trevi TherapeuticsN/A -63.31% -57.06% Arvinas N/A -50.26%-24.87% Which has more volatility & risk, TRVI or ARVN? Trevi Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Do insiders & institutionals have more ownership in TRVI or ARVN? 95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 24.4% of Trevi Therapeutics shares are owned by insiders. Comparatively, 5.2% of Arvinas shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryArvinas beats Trevi Therapeutics on 11 of the 17 factors compared between the two stocks. Ad Diversified Trading InstituteCombine the QQQ, IWM and SPY in one tradeIf you’ve been investing in the major indexes for the last 20 years, you may need a new strategy. Because the Dow Jones has returned just 349%... The Russell 2000 has returned just 397%... And the S&P 500 has returned just 450%. And although I can’t guarantee results or against losses… I want to tell you about my “2-Click Trade” that has encapsulated more than the return of ALL THREE OF THOSE INDEXES COMBINED… Plus, it targets multiple overnight payouts in a month with 84.3% accuracy! While I cannot promise future returns or against losses…You can find out about this “2-Click Trade” here. Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVI vs. The Competition Export to ExcelMetricTrevi TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$311.31M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-9.2010.5991.3417.19Price / SalesN/A195.381,117.70116.80Price / CashN/A57.1642.6437.86Price / Book3.145.104.794.78Net Income-$29.07M$151.51M$120.07M$225.60M7 Day Performance-2.88%-2.15%-1.90%-1.23%1 Month Performance48.35%-3.14%11.45%3.37%1 Year Performance197.79%11.50%30.63%16.58% Trevi Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVITrevi Therapeutics3.0381 of 5 stars$4.05-2.4%$9.31+129.9%+214.0%$311.31MN/A-9.2020Gap DownHigh Trading VolumeARVNArvinas2.0261 of 5 stars$19.35-0.8%$63.50+228.2%-49.3%$1.33B$78.50M-4.18445DAWNDay One Biopharmaceuticals1.6299 of 5 stars$12.74-0.1%$35.71+180.3%-7.7%$1.28B$101.95M-12.3860ARDXArdelyx3.6852 of 5 stars$5.39+3.3%$10.42+93.3%-18.9%$1.28B$251.85M-17.80267SYRESpyre Therapeutics1.7682 of 5 stars$24.65+2.2%$51.50+108.9%+53.4%$1.27B$890,000.00-3.23100CALTCalliditas Therapeutics AB (publ)0.0677 of 5 stars$40.00-0.4%$39.25-1.9%N/A$1.19B$1.60B-21.62180SPRYARS Pharmaceuticals2.9441 of 5 stars$12.26+3.0%$24.00+95.8%+121.8%$1.19B$30,000.00-23.3390Insider TradeNews CoverageANIPANI Pharmaceuticals4.8328 of 5 stars$56.07-0.9%$77.71+38.6%+1.9%$1.18B$555.46M-102.89642Insider TradeSNDXSyndax Pharmaceuticals3.96 of 5 stars$13.73-1.4%$37.64+174.1%-33.6%$1.17B$16M-3.84110News CoverageRCKTRocket Pharmaceuticals4.8481 of 5 stars$11.94-0.7%$51.00+327.1%-58.6%$1.09BN/A-4.37240Analyst ForecastBCYCBicycle Therapeutics3.6057 of 5 stars$15.46+11.9%$36.00+132.9%-18.8%$1.07B$26.98M-4.56240Analyst ForecastInsider TradeAnalyst RevisionNews CoverageHigh Trading Volume Related Companies and Tools Related Companies ARVN Alternatives DAWN Alternatives ARDX Alternatives SYRE Alternatives CALT Alternatives SPRY Alternatives ANIP Alternatives SNDX Alternatives RCKT Alternatives BCYC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRVI) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
